The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns

Ann Dermatol Venereol. 2024 Feb 6;151(1):103243. doi: 10.1016/j.annder.2023.103243. Online ahead of print.NO ABSTRACTPMID:38325268 | DOI:10.1016/j.annder.2023.103243

Source: Annales de Dermatologie et de Cenereologie - February 7, 2024 Category: Dermatology Authors: M Amini-Adle J-P Arnault F Aubin N Beneton G Bens F Brunet-Possenti P C élerier J Charles L Crumbach S Dalac S Darras J De Quatrebarbes M Dinulescu C Dutriaux C Gaudy E G érard D Giacchero F Granel-Brocard F Grange T Jouary N Kramkimel C Lebb é Y Le Co Source Type: research